マーケットレポート詳細

気管支炎治療薬：世界市場2027年予測

Bronchitis Treatments: Global Markets

出版元：BCC Research 　 出版元について
発行年：2022年11月
定価 ：Single User License(1名様ライセンス)US$5,500 (米国ドル) /2 to 5 Users License(5名様)$6,600 /Site License $7,920 / Enterprise License $9,504
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文98ページになります。
商品コード：BCC439

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

気管支炎治療薬の世界市場規模は、2022年の58億ドルから今後2027年には69億ドルへと拡大が予測されます。2022年から2027年にかけての同市場規模の平均年成長率は3.5%とレポートは分析しています。
当レポートでは、気管支炎治療薬の市場概要、各種セグメント別市場分析(タイプ別、薬剤クラス別、国地域別)、市場ダイナミクス、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

◆イントロダクション

・調査目的
・調査対象
・調査手法

◆サマリーと調査ハイライト

◆概要

◆市場ダイナミクス

・気管支炎治療薬市場に影響を与える要因
・ドライバー
・障壁

◆COVID-19の影響

・COVID-19の進行
・疫学

◆気管支炎治療薬市場：タイプ別

・急性気管支炎
・慢性気管支炎
※市場予測データ掲載-2027年

◆気管支炎治療薬市場：薬剤クラス別

・気管支拡張薬
・抗生物質
・抗炎症薬
※市場予測データ掲載-2027年

◆気管支炎治療薬市場：地域別

北米
・米国、カナダ、メキシコ
欧州
・英国、ドイツ、フランス
・その他欧州
アジア太平洋
・日本、中国、インド、韓国
・その他アジア太平洋
中南米
中東アフリカ
※地域別に主要国別の細分化データ掲載

◆気管支炎治療薬市場の主要企業プロフィール

・ASTRAZENECA
・BAYER AG
・BOEHRINGER INGELHEIM INTERNATIONAL GMBH
・CIPLA INC.
・DR. REDDY’S LABORATORIES LTD.
・GLAXOSMITHKLINE PLC
・MERCK & CO. INC.
・NOVARTIS AG
・PFIZER INC.
・SANOFI
・SUN PHARMACEUTICAL INDUSTRIES LTD.
・TEVA PHARMACEUTICAL INDUSTRIES LTD.

（全98頁）


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

CHAPTER 1 INTRODUCTION

1.1 STUDY GOALS AND OBJECTIVES
1.2 REASONS FOR DOING THIS STUDY
1.3 SCOPE OF THE REPORT
1.4 METHODOLOGY
1.5 GEOGRAPHIC BREAKDOWN
1.6 ANALYST’S CREDENTIALS
1.7 BCC CUSTOM RESEARCH
1.8 RELATED BCC RESEARCH REPORTS

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 OVERVIEW

3.1 INTRODUCTION

  • 3.1.1 DISEASE OVERVIEW
  • 3.1.2 BRONCHITIS TYPES
  • 3.1.3 PIPELINE DRUGS

CHAPTER 4 MARKET DYNAMICS

4.1 FACTORS AFFECTING THE MARKET FOR BRONCHITIS TREATMENTS
4.2 MARKET DRIVERS

  • 4.2.1 INCREASE IN THE SMOKERS
  • 4.2.2 GROWING GERIATRIC POPULATION
  • 4.2.3 RISE IN CHRONIC OBSTRUCTIVE PULMONARY DISORDER PATIENTS

4.3 MARKET RESTRAINTS

  • 4.3.1 STRINGENT REGULATIONS

CHAPTER 5 IMPACT OF COVID-19

5.1 COVID-19 PROGRESSION
5.2 EPIDEMIOLOGY

  • 5.2.1 COLLABORATION BETWEEN ORGANIZATIONS AND GOVERNMENTS
  • 5.2.2 SPREAD OF DISEASE

CHAPTER 6 GLOBAL MARKET FOR BRONCHITIS TREATMENTS BY TYPE

6.1 GLOBAL MARKET FOR BRONCHITIS TREATMENTS BY TYPE
6.2 ACUTE BRONCHITIS
6.3 CHRONIC BRONCHITIS

CHAPTER 7 GLOBAL MARKET FOR BRONCHITIS TREATMENTS BY DRUG CLASS

7.1 BRONCHODILATORS
7.2 ANTIBIOTICS
7.3 ANTI-INFLAMMATORIES

CHAPTER 8 GLOBAL MARKET FOR BRONCHITIS TREATMENTS BY REGION

8.1 NORTH AMERICA

  • 8.1.1 U.S.
  • 8.1.2 CANADA
  • 8.1.3 MEXICO

8.2 EUROPE

  • 8.2.1 U.K.
  • 8.2.2 GERMANY
  • 8.2.3 FRANCE
  • 8.2.4 REST OF EUROPE

8.3 ASIA-PACIFIC

  • 8.3.1 CHINA
  • 8.3.2 JAPAN
  • 8.3.3 INDIA
  • 8.3.4 SOUTH KOREA
  • 8.3.5 REST OF ASIA-PACIFIC

8.4 SOUTH AMERICA
8.5 MIDDLE EAST AND AFRICA

CHAPTER 9 COMPANY PROFILES

ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
CIPLA INC.
DR. REDDY’S LABORATORIES LTD.
GLAXOSMITHKLINE PLC
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.

 

LIST OF TABLES
SUMMARY TABLE A : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, THROUGH 2027
SUMMARY TABLE B : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY TYPE, THROUGH 2027
SUMMARY TABLE C : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY DRUG CLASS, THROUGH 2027
TABLE 1 : ASTRAZENECA PIPELINE DRUGS, 2022
TABLE 2 : COVID-19 CONFIRMED CASES AND DEATHS, BY WHO REGION, AS OF JUNE 15, 2022
TABLE 3 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, THROUGH 2027
TABLE 4 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY TYPE, THROUGH 2027
TABLE 5 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY REGION, THROUGH 2027
TABLE 6 : GLOBAL MARKET FOR ACUTE BRONCHITIS TREATMENTS, THROUGH 2027
TABLE 7 : GLOBAL MARKET FOR CHRONIC BRONCHITIS TREATMENTS, THROUGH 2027
TABLE 8 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY DRUG CLASS, THROUGH 2027
TABLE 9 : GLOBAL MARKET FOR BRONCHODILATORS FOR BRONCHITIS TREATMENT, THROUGH 2027
TABLE 10 : GLOBAL MARKET FOR ANTIBIOTICS FOR BRONCHITIS TREATMENT, BY, THROUGH 2027
TABLE 11 : GLOBAL MARKET FOR ANTI-INFLAMMATORIES FOR BRONCHITIS TREATMENT, THROUGH 2027
TABLE 12 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY REGION, THROUGH 2027
TABLE 13 : NORTH AMERICAN MARKET FOR BRONCHITIS TREATMENTS, BY COUNTRY, THROUGH 2027
TABLE 14 : EUROPEAN MARKET FOR BRONCHITIS TREATMENTS, BY COUNTRY, THROUGH 2027
TABLE 15 : ASIA-PACIFIC MARKET FOR BRONCHITIS TREATMENTS, BY COUNTRY, THROUGH 2027
TABLE 16 : SOUTH AMERICAN MARKET FOR BRONCHITIS TREATMENTS, THROUGH 2027
TABLE 17 : MIDDLE EAST AND AFRICAN MARKET FOR BRONCHITIS TREATMENTS, THROUGH 2027
TABLE 18 : ASTRAZENECA: FINANCIAL PERFORMANCE, 2018-2021
TABLE 19 : BAYER AG: MARKETED PRODUCTS
TABLE 20 : BAYER AG: NET REVENUE, 2016-2021
TABLE 21 : CIPLA’S KEY FINANCIALS 2021 AND 2022
TABLE 22 : DR. REDDY’S KEY FINANCIALS 2021
TABLE 23 : GLAXOSMITHKLINE: PRODUCT SEGMENT
TABLE 24 : GLAXOSMITHKLINE: KEY FINANCIALS 2021
TABLE 25 : GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 26 : MERCK & CO. INC.: BUSINESS SEGMENT
TABLE 27 : MERCK & CO. INC.: FINANCIAL PERFORMANCE, 2018-2021
TABLE 28 : NOVARTIS KEY FINANCIALS, 2021
TABLE 29 : NOVARTIS AG: KEY DEVELOPMENTS
TABLE 30 : PFIZER: BUSINESS SEGMENT
TABLE 31 : PFIZER INC. REVENUE, 2021
TABLE 32 : SANOFI: BUSINESS SEGMENT
TABLE 33 : SANOFI: FINANCIAL PERFORMANCE, 2021
TABLE 34 : SUN PHARMACEUTICAL: KEY FINANCIALS 2021
TABLE 35 : TEVA PHARMACEUTICAL INDUSTRIES KEY FINANCIALS 2021

LIST OF FIGURES
SUMMARY FIGURE A : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
SUMMARY FIGURE B : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY TYPE, 2020-2027
SUMMARY FIGURE C : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY DRUG CLASS, 2020-2027
FIGURE 1 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY TYPE, 2020-2027
FIGURE 2 : GLOBAL MARKET SHARES OF BRONCHITIS TREATMENTS, BY TYPE, 2021
FIGURE 3 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY REGION, 2020–2027
FIGURE 4 : GLOBAL MARKET FOR TREATMENTS FOR ACUTE BRONCHITIS, 2020-2027
FIGURE 5 : GLOBAL MARKET FOR CHRONIC BRONCHITIS TREATMENTS, 2020-2027
FIGURE 6 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY DRUG CLASS, 2020-2027
FIGURE 7 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY DRUG CLASS, 2021
FIGURE 8 : GLOBAL MARKET FOR BRONCHODILATORS FOR BRONCHITIS TREATMENT, 2020-2027
FIGURE 9 : GLOBAL MARKET FOR ANTIBIOTICS FOR BRONCHITIS TREATMENT, 2020-2027
FIGURE 10 : GLOBAL MARKET FOR ANTI-INFLAMMATORIES FOR BRONCHITIS TREATMENT, 2020-2027
FIGURE 11 : GLOBAL MARKET FOR BRONCHITIS TREATMENTS, BY REGION, 2020-2027
FIGURE 12 : GLOBAL MARKET SHARES OF BRONCHITIS TREATMENTS, BY REGION, 2021
FIGURE 13 : NORTH AMERICAN MARKET FOR BRONCHITIS TREATMENTS, BY COUNTRY 2020–2027
FIGURE 14 : U.S. MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 15 : CANADIAN MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 16 : MEXICAN MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 17 : EUROPEAN MARKET FOR BRONCHITIS TREATMENTS, BY COUNTRY, 2020-2027
FIGURE 18 : U.K. MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 19 : GERMAN MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 20 : FRENCH MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 21 : REST OF THE EUROPEAN MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 22 : ASIA-PACIFIC MARKET FOR BRONCHITIS TREATMENTS, BY COUNTRY, 2020-2027
FIGURE 23 : CHINESE MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 24 : JAPANESE MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 25 : INDIAN MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 26 : SOUTH KOREAN MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 27 : REST OF APAC MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 28 : SOUTH AMERICAN MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 29 : MIDDLE EAST AND AFRICAN MARKET FOR BRONCHITIS TREATMENTS, 2020-2027
FIGURE 30 : ASTRAZENECA: SALES SHARE, BY SEGMENT, 2021
FIGURE 31 : ASTRAZENECA: REVENUE SHARE, BY REGION, 2021
FIGURE 32 : BAYER AG: REVENUE SHARE, BY REGION, 2021
FIGURE 33 : BAYER AG: REVENUE SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 34 : BOEHRINGER INGELHEIM: ANNUAL REVENUE, 2021
FIGURE 35 : BOEHRINGER INGELHEIM: REVENUE SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 36 : BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2021
FIGURE 37 : DR. REDDY’S: REVENUE SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 38 : GLAXOSMITHKLINE PLC: NET REVENUE, 2016-2020
FIGURE 39 : GLAXOSMITHKLINE PLC: REVENUE SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 40 : GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2021
FIGURE 41 : MERCK & CO. INC.: REVENUE SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 42 : MERCK & CO. INC.: REVENUE SHARE, BY REGION, 2021
FIGURE 43 : NOVARTIS: REVENUE SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 44 : NOVARTIS: TOTAL REVENUE SHARE, BY REGION, 2021
FIGURE 45 : PFIZER INC.: REVENUE SHARE, BY REGION, 2021
FIGURE 46 : PFIZER INC.: REVENUE SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 47 : SANOFI: NET SALES SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 48 : SANOFI: NET SALES SHARE, BY REGION, 2021
FIGURE 49 : SUN PHARMACEUTICAL: REVENUE SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 50 : SUN PHARMACEUTICAL: TOTAL REVENUE SHARE, BY REGION, 2021
FIGURE 51 : TEVA: ANNUAL REVENUE, 2018-2020
FIGURE 52 : TEVA PHARMACEUTICAL INDUSTRIES: REVENUE SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 53 : TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE SHARE, BY REGION, 2021


△ 一番上に戻る